Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YP5U
|
|||
| Drug Name |
3-substituted-2-furancarboxylic acid hydrazide derivative 5
|
|||
| Synonyms |
PMID25828189-Compound-5
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
DAINIPPON SUMITOMO PHARMA CO [JP]
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H21N3O7
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)OCC2=CC=C(C=C2)C3=C(OC=C3)C(=O)NNC(=O)C4=CC(=C(C=C4)O)[N+](=O)[O-]
|
|||
| InChI |
1S/C26H21N3O7/c1-16-2-9-20(10-3-16)36-15-17-4-6-18(7-5-17)21-12-13-35-24(21)26(32)28-27-25(31)19-8-11-23(30)22(14-19)29(33)34/h2-14,30H,15H2,1H3,(H,27,31)(H,28,32)
|
|||
| InChIKey |
BTGUVNBWMLTDRT-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon receptor (GCGR) | Target Info | Antagonist | [1] |
| Target's Patent Info | Glucagon receptor (GCGR) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Glucagon signaling pathway | ||||
| Reactome | Glucagon signaling in metabolic regulation | |||
| G alpha (q) signalling events | ||||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.